Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)
![ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-459687-AntiSARSCoV2-Spike-Glycoprotein-S1-antibody-ELISA.jpg "ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)")
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Human monoclonal [CR3022] to SARS-CoV-2 Spike Glycoprotein S1
- Suitable for: Indirect ELISA, ELISA
Overview
-
Product name
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022]
See all SARS-CoV-2 Spike Glycoprotein S1 primary antibodies -
Description
Human monoclonal [CR3022] to SARS-CoV-2 Spike Glycoprotein S1 -
Host species
Human -
Tested applications
Suitable for: Indirect ELISA, ELISAmore details -
Species reactivity
Reacts with: SARS-CoV, SARS-CoV-2 -
Immunogen
Tissue, cells or virus corresponding to Human coronavirus SARS-CoV-2 Spike Glycoprotein S1. The original monoclonal antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV.
Database link: P59594 -
Epitope
This antibody binds the amino acids 318-510 in the S1 domain of the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein. The antibody also binds to P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope is only accessible in the "open" conformation of the spike protein (Joyce et al. 2020). -
General notes
The original CR3022 antibody was generated by sequencing peripheral blood lymphocytes of a patient exposed to the SARS-CoV. This antibody was shown to neutralize SARS-COV in a concerted action with clone CR3014. Presence of both antibodies delivers a blocking action of the SARS-COV RBD-ACE2 interaction, by binding two distinct and functional epitopes (16796401).
CR3022 has been shown to bind with a high affinity to SARS-CoV2 (32416259, 32413276). Structural modelling has confirmed that CR3022 targets a conserved epitope between SARS-CoV and SARS-CoV2 in the RBD domain (32245784, 32065055). Precisely, this antibody binds to the ‘open’ conformation of the spike protein to the amino acids 318-510 in the S1 domain of the SARS-CoV as well as SARS-CoV-2 strains (32245784, Joyce et al. 2020). The antibody is also able to bind the P462L-substituted S318–510 fragments of the SARS spike protein. The binding epitope of clone CR3022 does not overlap with the ACE2 binding site of SARS-COV2 (32065055). Therefore whilst CR3022 can neutralise SARS-COV in in a concerted action with clone CR3014, CR3022 is not believed to independently neutralise SARS-COV2, based on in vitro studies (32226289, 32065055, 32383254, 32416259).
Recombinant Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody (ab273073) is a Human IgG1 Recombinant version of CR3022 for research use only. CR3022 is also available as a chimeric rabbit antibody (ab273074).
Applications overview
Tick: Tested and Guaranteed to work X: Will not work —: No data
ab273073 was developed to have a human IgG1 isotype.
Other isotypes of clone CR3022 available:
ab278112 – human IgA
ab278111 – human IgM
ab273074 – rabbit IgG
ab273886 – rat IgG2a
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. -
Storage buffer
Preservative: 0.02% Proclin 300
Constituent: PBS -
Concentration information loading... -
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
CR3022 -
Isotype
IgG1 -
Light chain type
kappa -
Research areas
Associated products
-
Alternative Versions
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab273073 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| Indirect ELISA |
Use at an assay dependent concentration.
|
|
| ELISA |
Use at an assay dependent concentration.
|
| Notes |
|---|
|
Indirect ELISA
Use at an assay dependent concentration. |
|
ELISA
Use at an assay dependent concentration. |
Images
-
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)
ELISA using ab273073 and mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 µg/ml. Ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (Ab01680) exhibited exceptional binding to all mutant spike proteins. RBD WT – wild-type receptor binding domain.
-
![ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-459685-AntiSARSCoV2-Spike-Glycoprotein-S1-antibody-ELISA.jpg)
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)ELISA using ab273073 with UK (B.1.1.7) and South African (B.1.351 (501Y.V2)) mutant spike proteins. The plate was coated with the mutant spike protein variants (The Native Antigen Company) at 2.5 µg/ml. Ab01680 was conjugated to HRP and titrated on a 3-fold serial dilution starting at 1,000 ng/ml. CR3022 (Ab01680) exhibited exceptional binding to all mutant spike proteins. WT – wild type.
-
![Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-455570-Log-data--both-Ags-Ab273073-002.jpg)
Indirect ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)Indirect ELISA showing primary antibody ab273073 (CR3022, human chimeric) binding to the antigens ab272105 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (sheep Fc fusion)) and ab273068 (recombinant human coronavirus SARS-CoV-2 Spike Glycoprotein S1 (Active)). Plates were coated with 100ng/well ab272105 or ab273068 and binding of ab273073 assessed in serial dilution from 200ng/ml primary antibody in duplicate. Binding was detected using ab98624, an anti-human Fc secondary conjugated to HRP. Data are represented as the mean and error bars represent standard deviation.
-
![ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Chimeric (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-390575-anti-sars-cov2-spike-glycoprotei-s1-antibody-elisa-2.jpg)
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Chimeric (ab273073)Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein domains S1 and S2 of various origin.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), His-Tag (Insect Cells; grey line), SARS-CoV-2 Spike Glycoprotein (S2), His-Tag (Insect Cells; yellow line) and SARS Coronavirus Spike Glycoprotein (S1), His-Tag (HEK293 cells; blue line) at concentrations of 5 µg/ml. A 3-fold serial dilution from 41.6 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
-
![ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Chimeric (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-390576-anti-sars-cov2-spike-glycoprotei-s1-antibody-elisa.jpg)
ELISA - Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] - Chimeric (ab273073)Binding curve of ab273073 to SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag and SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag from HEK293 cells.
ELISA plate coated with SARS-CoV-2 Spike Glycoprotein (S1), Sheep Fc-Tag (blue line) or SARS-CoV-2 Spike Glycoprotein (S2), Sheep Fc-Tag (orange line) from HEK293 cells at concentrations of 5 µg/ml. A 3-fold serial dilution from 125 ng/ml was performed using ab273073.
For detection, a 1/4000 dilution of HRP-labelled anti-human IgG antibody was used.
-
![Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)](https://www.abcam.com/ps/products/273/ab273073/Images/ab273073-4-benefits-of-recombinant-antibodies.png)
Anti-SARS-CoV-2 Spike Glycoprotein S1 antibody [CR3022] (ab273073)
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (17)
ab273073 has been referenced in 17 publications.
- Schneider MM et al. Microfluidic characterisation reveals broad range of SARS-CoV-2 antibody affinity in human plasma. Life Sci Alliance 5:N/A (2022). PubMed: 34848436
- Mattioli IA et al. Graphene-based hybrid electrical-electrochemical point-of-care device for serologic COVID-19 diagnosis. Biosens Bioelectron 199:113866 (2022). PubMed: 34915214
- Fang Z et al. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nat Commun 13:3250 (2022). PubMed: 35668119
- Hwu AT et al. Centrifugal disc liquid reciprocation flow considerations for antibody binding to COVID antigen array during microfluidic integration. Lab Chip 22:2695-2706 (2022). PubMed: 35737382
- Sakamoto A et al. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. Vaccines (Basel) 10:N/A (2022). PubMed: 35746438